Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04938557
Other study ID # 240380
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 26, 2019
Est. completion date June 30, 2023

Study information

Verified date December 2023
Source Norfolk and Norwich University Hospitals NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Evaluation of the biomedical and psychosocial impact of automated Closed-Loop (Artificial Pancreas) insulin delivery in women with type 1 diabetes during pregnancy


Description:

An open-label, multi-centre, randomized, two-arm parallel group trial comparing automated closed-loop and standard insulin delivery. 124 pregnant women between 18 and 45 years of age with Type 1 Diabetes of at least 12 months' duration on standard insulin delivery (CSII or MDI) will be recruited through outpatient antenatal diabetes clinics. Women fulfilling the eligibility criteria will be randomized to automated insulin delivery (AiD) or to continue standard patient-directed insulin delivery (CSII or MDI) without AiD. The study will take place within the home and NHS antenatal clinical settings. Additional blood samples for the research will be obtained at the 24th and 34th week of pregnancy and questionnaires will also be completed by the participant at the 34th week of pregnancy. Following this we will collect information on the birth. 25 of the woman randomised to the closed loop insulin delivery system will also be interviewed to gain more information on, among other things, their existing diabetes management practices, everyday work and family lives and their experience with the device.


Recruitment information / eligibility

Status Completed
Enrollment 124
Est. completion date June 30, 2023
Est. primary completion date April 30, 2022
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: 1. Between 18 and 45 years of age (inclusive). 2. A diagnosis of type 1 diabetes (T1D), as defined by WHO for at least 12 months. 3. A viable pregnancy confirmed by ultrasound, up to 13 weeks and 6 days gestation. 4. Currently on intensive insulin therapy (=3 injections or CSII). 5. Willingness to use the study devices throughout the trial. 6. HbA1c level =48 mmol/mol (=6.5%) at booking (first antenatal contact) and =86 mmol/mol (=10%) at point of randomization. 7. Able to provide informed consent. 8. Have access to email. Exclusion Criteria: 1. Non-type 1 diabetes. 2. Any other physical or psychological disease which, in the opinion of the investigator, is likely to interfere with the normal conduct and interpretation of the study results e.g. untreated coeliac disease or untreated hypothyroidism. 3. Current treatment with drugs known to interfere with glucose metabolism as judged by the investigator such as high dose systemic corticosteroids, non-selective beta-blockers and MAO inhibitors. 4. Known or suspected allergy against insulin. 5. Women with advanced nephropathy (eGFR <45), severe autonomic neuropathy, uncontrolled gastroparesis or severe proliferative retinopathy, as judged by the investigator, that is likely to interfere with the normal conduct of the study and interpretation of study results. 6. Very good or very poor glycaemic control i.e. first antenatal HbA1c <48 mmol/mol (<6.5%) and current HbA1c >10% (>86 mmol/mol). Women who enter pregnancy with HbA1c >10% (>86 mmol/mol) may participate if they achieve HbA1c =10% (=86 mmol/mol) before randomization. 7. Total daily insulin dose 1.5 IU/kg. 8. Severe visual or hearing impairment. 9. Unable to speak and understand English.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Automated closed-loop insulin delivery (AiD)
Closed-loop systems are designed to deliver insulin in response to CGM glucose levels and may help to improve glucose control above and beyond what is currently achievable using insulin pumps, injections and CGM without AiD.
A standard insulin delivery system
Self-directed insulin delivery for pregnant women with T1D, which is insulin pump or MDI.

Locations

Country Name City State
United Kingdom Norfolk and Norwich University Hospitals NHS Foundation Trust Norwich Norfolk

Sponsors (8)

Lead Sponsor Collaborator
Norfolk and Norwich University Hospitals NHS Foundation Trust Belfast Health and Social Care Trust, King's College London, University of Cambridge, University of East Anglia, University of Edinburgh, University of Glasgow, University of Leeds

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary The time spent with glucose levels between 3.5-7.8 mmol/L based on CGM measures (Time In Range TIR 3.5-7.8mmol/L) The primary outcome is the percentage of time spent with glucose levels between 3.9-7.8 mmol/L based on CGM levels between 16 weeks gestation and delivery.as compared with standard self-directed insulin delivery in pregnant women with T1D. Between 16 weeks gestation and delivery - an average of 18 weeks
Secondary CGM glucose measures The time spent with CGM glucose levels above and below target range, using the mean CGM glucose and CGM glucose variability measures (CV, SD). Between 16 weeks gestation and delivery - an average of 18 weeks
Secondary CGM glucose index (Low) The Low Blood Glucose Index (LBGI) Between 16 weeks gestation and delivery - an average of 18 weeks
Secondary CGM glucose index (High) High Blood Glucose Index (HBGI) measures Between 16 weeks gestation and delivery - an average of 18 weeks
Secondary HbA1c testing (Maternal) To assess the change of HbA1c in the maternal level. Blood samples will be collected at baseline, 24-26 weeks, 34-36 weeks
Secondary Diabetic ketoacidosis. The frequency and severity of diabetic ketoacidosis An average of 24 weeks
Secondary Severe hypoglycaemia episodes. The frequency and severity of hypoglycaemia episodes defined as CGM glucose levels <3.5 mmol/L (level 1 hypoglycaemia) and <2.8 mmol/L (level 2 hypoglycaemia) for at least 15 minutes. Distinct episodes must be separated for at least 30 minutes. An average of 24 weeks
Secondary The number and severity of episodes of adverse device effect. Adverse events including pregnancy loss, stillbirth, neonatal death <24 weeks gestation until delivery - an average of 16 weeks
Secondary Hospital length of stay (maternal). Hospital length of stay (all admissions including the delivery admission) Between 13 and 40 weeks - an average of 24 weeks
Secondary Mode of delivery How the infant is delivered, for example: vaginal, instrumental, elective caesarean section and emergency caesarean section) At >34 weeks (delivery)
Secondary Gestational age at delivery The gestational age at delivery and indication for any preterm delivery (<37 weeks). Measured in years. At >34 weeks (delivery)
Secondary Infant birth weight (LGA) Infant birth weight (customised birth weight percentile, incidence of large for gestational age (LGA). At >34 weeks (delivery)
Secondary Infant birth weight (SGA). Infant birth weight (customised birth weight percentile, incidence of small for gestational age (SGA). At >34 weeks (delivery)
Secondary Neonatal morbidity (hypoglycaemia, jaundice, respiratory distress). Neonatal morbidity including treatment for neonatal hypoglycaemia, neonatal jaundice and respiratory distress. Between delivery and 40 weeks - an average of 6 weeks
Secondary Neonatal intensive care unit (NICU) admission. Neonatal intensive care unit (NICU) admission >24 hours NICU admission after 24 hours
Secondary Hospital length of stay (infant). Hospital length of stay for the infant Between delivery and 40 weeks - an average of 6 weeks
See also
  Status Clinical Trial Phase
Completed NCT05594446 - Morphometric Study of the Legs and Feet of Diabetic Patients in Order to Collect Data Intended to be Used to Measure by Dynamometry the Pressures Exerted by Several Medical Compression Socks at the Level of the Forefoot
Completed NCT03975309 - DHS MIND Metabolomics
Completed NCT01855399 - Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes N/A
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Recruiting NCT04984226 - Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD Phase 2
Recruiting NCT05007990 - Caregiving Networks Across Disease Context and the Life Course
Active, not recruiting NCT04420936 - Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care for Our Program N/A
Recruiting NCT03549559 - Imaging Histone Deacetylase in the Heart N/A
Completed NCT04903496 - Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional Database
Completed NCT01437592 - Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects Phase 1
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT03390179 - Hyperglycemic Response and Steroid Administration After Surgery (DexGlySurgery)
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Recruiting NCT05294822 - Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes N/A
Completed NCT04427982 - Dance and Diabetes/Prediabetes Self-Management N/A
Completed NCT02356848 - STEP UP to Avert Amputation in Diabetes N/A
Completed NCT03292185 - A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects Phase 1
Active, not recruiting NCT05477368 - Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes N/A
Completed NCT04496401 - PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus Phase 4